T2 Biosystems (NASDAQ:TTOO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of T2 Biosystems (NASDAQ:TTOO) in a report released on Friday morning. The brokerage issued a sell rating on the medical equipment provider’s stock.

T2 Biosystems Price Performance

Shares of TTOO stock opened at $0.35 on Friday. The company’s fifty day simple moving average is $0.73 and its two-hundred day simple moving average is $2.76. T2 Biosystems has a 1 year low of $0.31 and a 1 year high of $8.38.

Institutional Trading of T2 Biosystems

A hedge fund recently bought a new stake in T2 Biosystems stock. Armistice Capital LLC purchased a new position in T2 Biosystems, Inc. (NASDAQ:TTOO) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,658,000 shares of the medical equipment provider’s stock, valued at approximately $8,854,000. Armistice Capital LLC owned about 9.49% of T2 Biosystems as of its most recent SEC filing. 23.18% of the stock is currently owned by institutional investors and hedge funds.

T2 Biosystems Company Profile

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.